Zealand Pharma A/S Q2 2024 Earnings Report

Zealand Pharma A/S EPS Results

• Actual EPS: -$0.67
• Consensus EPS: -$0.61
• Beat/Miss: Missed by -$0.06
• One Year Ago EPS: N/A

Zealand Pharma A/S Revenue Results

• Actual Revenue: $4.93 million
• Expected Revenue: $0.50 million
• Beat/Miss: Beat by +$4.43 million
• YoY Revenue Growth: N/A

Zealand Pharma A/S Announcement Details

• Quarter: Q2 2024
• Date: 8/15/2024
• Time: N/A

Zealand Pharma A/S (OTCMKTS:ZLDPF), a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.